Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Long-Term Debt Repayments (2018 - 2024)

Zevra Therapeutics' Long-Term Debt Repayments history spans 7 years, with the latest figure at $42.7 million for Q2 2024.

  • For Q2 2024, Long-Term Debt Repayments rose 20528.02% year-over-year to $42.7 million; the TTM value through Sep 2025 reached $42.7 million, down 9.97%, while the annual FY2024 figure was $42.7 million, 143.57% up from the prior year.
  • Long-Term Debt Repayments reached $42.7 million in Q2 2024 per ZVRA's latest filing, up from $4.7 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $42.7 million in Q2 2024 to a low of -$207000.0 in Q3 2023.
  • Average Long-Term Debt Repayments over 3 years is $16.4 million, with a median of $8.8 million recorded in 2023.
  • The largest YoY upside for Long-Term Debt Repayments was 20528.02% in 2024 against a maximum downside of 20528.02% in 2024.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $37.9 million in 2021, then plummeted by 87.53% to $4.7 million in 2023, then skyrocketed by 802.56% to $42.7 million in 2024.
  • Per Business Quant, the three most recent readings for ZVRA's Long-Term Debt Repayments are $42.7 million (Q2 2024), $4.7 million (Q4 2023), and -$207000.0 (Q3 2023).